Research has shown the role of growth factors in lung cancer angiogenesis. Angiogenesis promotes lung cancer progression by stimulating tumor growth, enhancing tumor invasion, contributing to metastasis, and modifying immune system responses within the tumor microenvironment. As a result, new treatment techniques based on the anti-angiogenic characteristics of compounds have been developed. These compounds selectively block the growth factors themselves, their receptors, or the downstream signaling pathways activated by these growth factors. The EGF and VEGF families are the primary targets in this approach, and several studies are being conducted to propose anti-angiogenic drugs that are increasingly suitable for the treatment of lung cancer, either as monotherapy or as combined therapy. The efficacy of the results are encouraging, but caution must be placed on the higher risk of toxicity, outlining the importance of personalized follow-up in the management of these patients.
研究表明，生长因子在肺癌血管生成中发挥着重要作用。血管生成通过刺激肿瘤生长、增强肿瘤侵袭性、促进转移以及改变肿瘤微环境中的免疫系统反应，从而推动肺癌进展。因此，基于化合物抗血管生成特性的新型治疗技术得以发展。这些化合物选择性阻断生长因子本身、其受体或由这些生长因子激活的下游信号通路。表皮生长因子（EGF）和血管内皮生长因子（VEGF）家族是该疗法的主要靶点，目前多项研究正在推进，旨在开发更适合肺癌治疗的抗血管生成药物，无论是作为单一疗法还是联合疗法。虽然疗效结果令人鼓舞，但必须警惕其较高的毒性风险，这凸显了在患者管理中实施个体化随访的重要性。
Angiogenesis in Lung Cancer: Understanding the Roles of Growth Factors
肿瘤(癌症)患者之家